• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

检查点激酶 1(Chk1)-短是 Chk1 的剪接变体和内源性抑制剂,它调节细胞周期和 DNA 损伤检查点。

Checkpoint kinase 1 (Chk1)-short is a splice variant and endogenous inhibitor of Chk1 that regulates cell cycle and DNA damage checkpoints.

机构信息

Department of Cellular Biology and Anatomy, Medical College of Georgia, Georgia Health Sciences University, Augusta, GA 30912, USA.

出版信息

Proc Natl Acad Sci U S A. 2012 Jan 3;109(1):197-202. doi: 10.1073/pnas.1104767109. Epub 2011 Dec 19.

DOI:10.1073/pnas.1104767109
PMID:22184239
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3252905/
Abstract

Checkpoint kinase 1 (Chk1) is a key regulator of checkpoint signaling in both the unperturbed cell cycle and DNA damage response. Under these conditions, Chk1 becomes active to prevent premature CDK1 activation and mitotic entry until DNA is properly replicated or repaired. It is unclear how Chk1 activity is controlled in the unperturbed cell cycle. During DNA damage, Chk1 is activated by ataxia telangiectasia and Rad3 related (ATR)-mediated phosphorylation; however, it is not entirely clear how this phosphorylation results in Chk1 activation. Here we report an N-terminally truncated alternative splice variant of Chk1, Chk1-S. Importantly, we show that Chk1-S is an endogenous repressor and regulator of Chk1. In the unperturbed cell cycle, Chk1-S interacts with and antagonizes Chk1 to promote the S-to-G2/M phase transition. During DNA damage, Chk1 is phosphorylated, which disrupts the Chk1-Chk1-S interaction, resulting in free, active Chk1 to arrest the cell cycle and facilitate DNA repair. Higher levels of Chk1-S are expressed, along with Chk1, in fetal and cancer tissues than in normal tissues. However, forced overexpression of Chk1-S in cultured cells and tumor xenografts induces premature mitotic entry, mitotic catastrophe, and reduction of tumor growth. The identification of Chk1-S as a unique splice variant and key regulator of Chk1 provides insights into cell cycle regulation and DNA damage response.

摘要

细胞周期检验点激酶 1(Chk1)是细胞周期和 DNA 损伤反应中检验点信号的关键调节因子。在这些条件下,Chk1 会变得活跃,以防止 CDK1 过早激活和有丝分裂进入,直到 DNA 被正确复制或修复。目前尚不清楚 Chk1 在未受干扰的细胞周期中如何被控制。在 DNA 损伤期间,Chk1 被共济失调毛细血管扩张症和 Rad3 相关蛋白(ATR)介导的磷酸化激活;然而,尚不清楚这种磷酸化如何导致 Chk1 激活。在这里,我们报告了 Chk1 的一种 N 端截断的替代剪接变体 Chk1-S。重要的是,我们表明 Chk1-S 是 Chk1 的内源性抑制剂和调节剂。在未受干扰的细胞周期中,Chk1-S 与 Chk1 相互作用并拮抗 Chk1,以促进 S 期到 G2/M 期的转变。在 DNA 损伤期间,Chk1 被磷酸化,这破坏了 Chk1-Chk1-S 相互作用,导致游离的、活跃的 Chk1 使细胞周期停滞并促进 DNA 修复。与正常组织相比,胎儿组织和癌组织中 Chk1 和 Chk1-S 的表达水平更高。然而,在培养细胞和肿瘤异种移植中强制过表达 Chk1-S 会导致有丝分裂过早进入、有丝分裂灾难和肿瘤生长减少。Chk1-S 作为一种独特的剪接变体和 Chk1 的关键调节剂的鉴定为细胞周期调控和 DNA 损伤反应提供了新的见解。

相似文献

1
Checkpoint kinase 1 (Chk1)-short is a splice variant and endogenous inhibitor of Chk1 that regulates cell cycle and DNA damage checkpoints.检查点激酶 1(Chk1)-短是 Chk1 的剪接变体和内源性抑制剂,它调节细胞周期和 DNA 损伤检查点。
Proc Natl Acad Sci U S A. 2012 Jan 3;109(1):197-202. doi: 10.1073/pnas.1104767109. Epub 2011 Dec 19.
2
Cutting edge: Chk1 directs senescence and mitotic catastrophe in recovery from G₂ checkpoint arrest.前沿:Chk1 在从 G₂ 检验点阻滞恢复时指导衰老和有丝分裂灾难。
J Cell Mol Med. 2011 Jul;15(7):1528-41. doi: 10.1111/j.1582-4934.2010.01143.x.
3
Combination drug scheduling defines a "window of opportunity" for chemopotentiation of gemcitabine by an orally bioavailable, selective ChK1 inhibitor, GNE-900.联合药物方案通过一种口服生物利用度高、选择性 ChK1 抑制剂 GNE-900,为 gemcitabine 的化学增敏作用定义了“机会之窗”。
Mol Cancer Ther. 2013 Oct;12(10):1968-80. doi: 10.1158/1535-7163.MCT-12-1218. Epub 2013 Jul 19.
4
DNA damage-induced accumulation of centrosomal Chk1 contributes to its checkpoint function.DNA损伤诱导的中心体Chk1积累有助于其检查点功能。
Cell Cycle. 2007 Oct 15;6(20):2541-8. doi: 10.4161/cc.6.20.4810. Epub 2007 Jul 30.
5
Analysis of Rad3 and Chk1 protein kinases defines different checkpoint responses.对Rad3和Chk1蛋白激酶的分析确定了不同的检查点反应。
EMBO J. 1998 Dec 15;17(24):7239-49. doi: 10.1093/emboj/17.24.7239.
6
Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor.LY2603618的特性及临床前开发:一种选择性强效Chk1抑制剂
Invest New Drugs. 2014 Apr;32(2):213-26. doi: 10.1007/s10637-013-0036-7. Epub 2013 Oct 10.
7
Checkpoint kinase 1 in DNA damage response and cell cycle regulation.检查点激酶 1 在 DNA 损伤反应和细胞周期调控中的作用。
Cell Mol Life Sci. 2013 Nov;70(21):4009-21. doi: 10.1007/s00018-013-1307-3. Epub 2013 Mar 19.
8
Mitotic DNA damage response: Polo-like kinase-1 is dephosphorylated through ATM-Chk1 pathway.有丝分裂 DNA 损伤反应:Polo 样激酶-1 通过 ATM-Chk1 途径去磷酸化。
Cell Cycle. 2010 Jun 15;9(12):2389-98. doi: 10.4161/cc.9.12.11904.
9
Chk1 is dispensable for G2 arrest in response to sustained DNA damage when the ATM/p53/p21 pathway is functional.当 ATM/p53/p21 通路功能正常时,Chk1 在应对持续的 DNA 损伤导致的 G2 期阻滞中是可有可无的。
Oncogene. 2011 Oct 13;30(41):4261-74. doi: 10.1038/onc.2011.135. Epub 2011 May 2.
10
Cdk-mediated phosphorylation of Chk1 is required for efficient activation and full checkpoint proficiency in response to DNA damage.Cdk 介导的 Chk1 磷酸化对于 DNA 损伤后 Chk1 的有效激活和充分发挥 checkpoint 功能是必需的。
Oncogene. 2012 Mar 1;31(9):1086-94. doi: 10.1038/onc.2011.310. Epub 2011 Jul 18.

引用本文的文献

1
Integrative modeling uncovers p21-driven drug resistance and prioritizes therapies for PIK3CA-mutant breast cancer.整合建模揭示了p21驱动的耐药性,并为PIK3CA突变型乳腺癌确定了优先治疗方案。
NPJ Precis Oncol. 2024 Jan 26;8(1):20. doi: 10.1038/s41698-024-00496-y.
2
3D spheroid culturing of Astyanax mexicanus liver-derived cell lines recapitulates distinct transcriptomic and metabolic states of in vivo tissue environment.墨西哥脂鲤肝脏细胞系的 3D 球体培养物再现了体内组织环境的独特转录组和代谢状态。
J Exp Zool B Mol Dev Evol. 2024 May;342(3):301-312. doi: 10.1002/jez.b.23236. Epub 2024 Jan 8.
3
Zinc finger protein 24-dependent transcription factor SOX9 up-regulation protects tubular epithelial cells during acute kidney injury.锌指蛋白 24 依赖性转录因子 SOX9 的上调在急性肾损伤期间保护管状上皮细胞。
Kidney Int. 2023 Jun;103(6):1093-1104. doi: 10.1016/j.kint.2023.02.026. Epub 2023 Mar 13.
4
RNA splicing dysregulation and the hallmarks of cancer.RNA 剪接失调与癌症的特征。
Nat Rev Cancer. 2023 Mar;23(3):135-155. doi: 10.1038/s41568-022-00541-7. Epub 2023 Jan 10.
5
Construction of a Versatile, Programmable RNA-Binding Protein Using Designer PPR Proteins and Its Application for Splicing Control in Mammalian Cells.利用设计的 PPR 蛋白构建一种通用、可编程的 RNA 结合蛋白及其在哺乳动物细胞剪接控制中的应用。
Cells. 2022 Nov 8;11(22):3529. doi: 10.3390/cells11223529.
6
Non-ubiquitous expression of core spliceosomal protein SmB/B' in chick and mouse embryos.在鸡和鼠胚胎中核心剪接体蛋白 SmB/B' 的非普遍表达。
Dev Dyn. 2023 Feb;252(2):276-293. doi: 10.1002/dvdy.537. Epub 2022 Sep 20.
7
Kidney toxicity of the BRAF-kinase inhibitor vemurafenib is driven by off-target ferrochelatase inhibition.BRAF 激酶抑制剂 vemurafenib 的肾毒性是由非靶标亚铁螯合酶抑制引起的。
Kidney Int. 2021 Dec;100(6):1214-1226. doi: 10.1016/j.kint.2021.08.022. Epub 2021 Sep 15.
8
On Broken Ne(c)ks and Broken DNA: The Role of Human NEKs in the DNA Damage Response.论断裂的颈(necks)和断裂的 DNA:人类 NEKs 在 DNA 损伤反应中的作用。
Cells. 2021 Feb 27;10(3):507. doi: 10.3390/cells10030507.
9
Involvement of the CDKL5-SOX9 signaling axis in rhabdomyolysis-associated acute kidney injury.CDKL5-SOX9 信号轴在横纹肌溶解相关急性肾损伤中的作用。
Am J Physiol Renal Physiol. 2020 Nov 1;319(5):F920-F929. doi: 10.1152/ajprenal.00429.2020. Epub 2020 Oct 12.
10
Ribociclib mitigates cisplatin-associated kidney injury through retinoblastoma-1 dependent mechanisms.瑞波西利通过视网膜母细胞瘤蛋白 1 依赖性机制减轻顺铂相关性肾损伤。
Biochem Pharmacol. 2020 Jul;177:113939. doi: 10.1016/j.bcp.2020.113939. Epub 2020 Mar 27.

本文引用的文献

1
RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma.RNAi 筛选蛋白激酶组发现细胞检查点激酶 1(CHK1)是神经母细胞瘤的治疗靶点。
Proc Natl Acad Sci U S A. 2011 Feb 22;108(8):3336-41. doi: 10.1073/pnas.1012351108. Epub 2011 Feb 2.
2
hMSH2 recruits ATR to DNA damage sites for activation during DNA damage-induced apoptosis.hMSH2 将 ATR 募集到 DNA 损伤部位,以便在 DNA 损伤诱导的细胞凋亡过程中被激活。
J Biol Chem. 2011 Mar 25;286(12):10411-8. doi: 10.1074/jbc.M110.210989. Epub 2011 Feb 1.
3
Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics.释放刹车导致的死亡:CHK1 抑制剂作为癌症治疗药物。
Trends Mol Med. 2011 Feb;17(2):88-96. doi: 10.1016/j.molmed.2010.10.009. Epub 2010 Nov 17.
4
Chk1 promotes replication fork progression by controlling replication initiation.Chk1 通过控制复制起始来促进复制叉的推进。
Proc Natl Acad Sci U S A. 2010 Sep 14;107(37):16090-5. doi: 10.1073/pnas.1005031107. Epub 2010 Aug 30.
5
Genetic instability and mammary tumor formation in mice carrying mammary-specific disruption of Chk1 and p53.携带 Chk1 和 p53 乳腺特异性敲除的小鼠中的遗传不稳定性和乳腺肿瘤形成。
Oncogene. 2010 Jul 15;29(28):4007-17. doi: 10.1038/onc.2010.163. Epub 2010 May 17.
6
New insights into checkpoint kinase 1 in the DNA damage response signaling network.在 DNA 损伤反应信号网络中对检查点激酶 1 的新认识。
Clin Cancer Res. 2010 Jan 15;16(2):376-83. doi: 10.1158/1078-0432.CCR-09-1029. Epub 2010 Jan 12.
7
Targeting the checkpoint kinase Chk1 in cancer therapy.在癌症治疗中靶向细胞周期检查点激酶 Chk1。
Cell Cycle. 2010 Jan 15;9(2):279-83. doi: 10.4161/cc.9.2.10445. Epub 2010 Jan 27.
8
Chk1 C-terminal regulatory phosphorylation mediates checkpoint activation by de-repression of Chk1 catalytic activity.Chk1 C 末端调节性磷酸化通过解除对 Chk1 催化活性的抑制来介导检查点激活。
Oncogene. 2009 Jun 18;28(24):2314-23. doi: 10.1038/onc.2009.102. Epub 2009 May 4.
9
Regulation of chk1.chk1 的调控。
Cell Div. 2009 Apr 29;4:8. doi: 10.1186/1747-1028-4-8.
10
Essential function of Chk1 can be uncoupled from DNA damage checkpoint and replication control.Chk1的基本功能可以与DNA损伤检查点和复制控制脱钩。
Proc Natl Acad Sci U S A. 2008 Dec 30;105(52):20752-7. doi: 10.1073/pnas.0806917106. Epub 2008 Dec 17.